Prosecution Insights
Last updated: April 19, 2026

Regenxbio Inc.

12 pending office actions

Portfolio Summary

12
Total Pending OAs
4
Final Rejections
8
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19234245 TREATMENT OF DYSTROPHINOPATHIES WITH MICRODYSTROPHIN GENE THERAPY CONSTRUCTS LEVIN, JOEL D 1633 Final Rejection Jun 10, 2025
18559078 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY AND COMBINATIONS THEREOF BABIC, CHRISTOPHER M 1633 Non-Final OA Nov 06, 2023
18558495 NOVEL AAV VECTORS AND METHODS AND USES THEREOF NICOL, ALEXANDER W 1634 Non-Final OA Nov 01, 2023
18261551 IMPROVED PRODUCTION OF RECOMBINANT POLYPEPTIDES AND VIRUSES YU, DELPHINUS DOU YI 1636 Non-Final OA Jul 14, 2023
18257820 METHOD OF PRODUCING A RECOMBINANT VIRUS PARTICLE LY, KRISTINA ELISABETH 1671 Non-Final OA Jun 15, 2023
18034042 VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS HUMPHRIES, NICHOLAS ADAM 1631 Non-Final OA Apr 26, 2023
17638517 TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB PENNINGTON, KATIE LEIGH 1634 Non-Final OA Feb 25, 2022
17628517 ENGINEERED NUCLEIC ACID REGULATORY ELEMENT AND METHODS OF USES THEREOF MATALKAH, FATIMAH KHALAF 1638 Final Rejection Jan 19, 2022
17600377 Gene Therapy For Eye Pathologies PARAS JR, PETER 1632 Final Rejection Sep 30, 2021
17292750 GENE THERAPY FOR NEURONAL CEROID LIPOFUSCINOSES ARON, KIMBERLY A 1633 Non-Final OA May 11, 2021
17285362 METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES YU, TIAN NMN 1681 Non-Final OA Apr 14, 2021
17050942 SYSTEMS AND METHODS OF SPECTROPHOTOMETRY FOR THE DETERMINATION OF GENOME CONTENT, CAPSID CONTENT AND FULL/EMPTY RATIOS OF ADENO-ASSOCIATED VIRUS PARTICLES FONSECA LOPEZ, FRANCINI ALVARENGA 1685 Final Rejection Oct 27, 2020

Managing Regenxbio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month